Stopped: due to reason 3 in the protocol- any new information becomes available during the trial that necessitates stopping the trial. New information became available with device no longer being investigational.
Endovascular middle meningeal artery (MMA) embolization is an emerging treatment for chronic subdural hematoma (cSDH). There is preliminary data to suggest that this minimally invasive therapy may be more efficacious and equally as safe compared to conventional, more invasive surgery. This study seeks to assess the safety and efficacy of middle meningeal artery embolization for chronic subdural hematoma as an adjunct to standard treatments, which include medical management and surgical evacuation.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of patients with recurrent or refractory hematoma (Radiographic resolution)
Timeframe: A head CT will be repeated 24 hours after the procedure, 7-10 days, 30 days, and 90 days post procedure to measure any change in size of the SDH compared to pre-procedure size
Number of patients requiring secondary evacuation surgery (Treatment Efficacy)
Timeframe: Evacuation surgery required within the 90 day follow up period